Corey Speers
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
403
Citations
4,433
Est. group size
~38
Recurring co-author estimate
Active years
24
Publishing since 2003
Typically publishes in teams of ~7 · 18% small-team papers (≤3 authors) · across 19 venues
- Abstract PS3-01-22: Targeting Disparities: Impact of Mammographic Screening and Social Drivers on Advanced-Stage Triple-Negative Breast Cancer in Vulnerable Populations Across US Counties
Clinical Cancer Research · 2026
- Abstract PS3-02-27: A Screening Paradox in TNBC: Exploring communities with High Late-stage Diagnosis Despite High Screening Uptake
Clinical Cancer Research · 2026
- External validation of a MMAI model for prognosis and chemotherapy benefit prediction in postmenopausal, node-positive, hormone receptor–positive breast cancer patients: Analysis of SWOG S8814.
Journal of Clinical Oncology · 2026
- Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers
Journal of Clinical Oncology · 2025
- Impact of Chemotherapy on Financial Toxicity in African American Breast Cancer Patients
American Journal of Clinical Oncology · 2025
- Radiation therapy for lobular breast cancer: opportunities and challenges for leveraging radiosensitivity
npj Breast Cancer · 2025
- Quantification and Qualification of Breast Cancer Patient Navigation from the Navigator-Assisted Hypofractionation (NAVAH) Phase I Clinical Trial
International Journal of Radiation Oncology*Biology*Physics · 2025
- Rx for Resilience: Curing Burnout in Oncology Through Smarter Workflows and Supportive Practices
JCO Oncology Practice · 2025
- Generative AI Enables Breast Cancer Genomic Subtype Prediction from Histology Images
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Impact of chemotherapy on financial toxicity in African-American breast cancer patients: Early findings from the navigator-assisted hypofractionation (NAVAH) phase I clinical trial.
Journal of Clinical Oncology · 2025
- Abstract P3-12-14: Real world data with standard (SD) and reduced dose (RD) sacituzumab-govitecan (SG) in metastatic triple negative (TNBC) and ER+/HER2- metastatic breast cancer (mBC)
Clinical Cancer Research · 2025
- Abstract P3-05-07: Early Pilot Results From the Navigator-Assisted Hypofractionation (NAVAH) Program to Aid African-American Breast Cancer Patients
Clinical Cancer Research · 2025
- Abstract P2-11-19: Unique kinetics of myeloid derived suppressor cell (MDSC) accumulation associated with immune related adverse events (irAEs) in patients with early stage triple negative breast cancer (eTNBC) receiving neoadjuvant chemo-immunotherapy
Clinical Cancer Research · 2025
- Abstract P5-09-15: Impact of Patient Navigation on Radiation Therapy Completion in Black Breast Cancer Patients: Early Phase I Trial Results From the Navigator-Assisted Hypofractionation (NAVAH) Program
Clinical Cancer Research · 2025
- Overlooked Risk in Cancer Care: Failure of Medical Reconciliation
JCO Oncology Practice · 2025
- Cancer Research×51
- International Journal of Radiation Oncology*Biology*Physics×24
- Clinical Cancer Research×20
- Journal of Clinical Oncology×13
- Neoplasia×7
- Lori J. Pierce
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Tasha M. Hughes
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Arya Mariam Roy
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Kai Johnson
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Kathleen Kemmer
Biochemistry, Genetics and Molecular Biology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile